Neuropace

NPCE

Market cap $556M

NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG data to speed ECoG review and insights.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will participate in the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting, taking place May 29 – June 2, 2026 in Cleveland, Ohio. At the meeting, NeuroPace will highlight the expanding role of responsive neuromodulation in epilepsy care, including long-term clinical out.

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced FDA approval of ECoG Assistant, its first AI-driven clinician-enabled feature. This milestone represents an important step in NeuroPace's broader AI platform strategy, leveraging the world's only long-term intracranial EEG dataset to transform how epilepsy is monitored and managed. ECoG Assistant: Treatment Insights Si.

NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and pricing actions support margins.

NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud workflow tools as 2026 revenue guidance rises.

NPCE bets on AI ECoG Assistant and cloud upgrades as it refocuses on RNS, while IGE label review and coverage timing loom.

NeuroPace raises revenue guidance for 2026 after Q1 sales beat estimates and losses narrow, driven by strong RNS System growth.

NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript

NeuroPace NASDAQ: NPCE raised its 2026 revenue outlook after reporting first-quarter results that management said reflected continued demand for its RNS System and improving commercial execution across epilepsy treatment centers.

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.21 per share a year ago.